Quarterly Results
MRNA
FY2025Q3
07:00:00
Pre-Market
Revenue
$1.02B
+16.80%
EPS
-$0.51
+76.28%
Al Prediction
-AI Summary
Slide
Attend WebcastMRNA
FY2025Q2
06:35:00
Pre-Market
Revenue
$142.00M
+26.15%
EPS
-$2.13
+28.76%
Al Prediction
-AI Summary
SlideAttend WebcastMRNA
FY2025Q1
06:38:00
Pre-Market
Revenue
$108.00M
-6.35%
EPS
-$2.52
+13.70%
Al Prediction
-AI Summary
Attend WebcastMRNA Earnings Forecast
Looking ahead, MRNA remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 633.09M and an EPS of -2.76.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -0.67%, while EPS estimates have been Revise Downward by -15.96%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Downward by -14.94% . These revisions correlate with a 27.84% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in MRNA long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Revenue Estimates for FY2025
Revise Downward
-0.67%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-15.96%
In Past 3 Month
Unlock the reason behind revisions!
Revenue Estimates for Q4 2025
Revise Downward
-14.94%
In Past 3 Month
Stock Price
Go Up
+27.84%
In Past 3 Month
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how MRNA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MRNA sees a +7.79% change in stock price 10 days leading up to the earnings, and a -3.23% change 10 days following the report. On the earnings day itself, the stock moves by -0.36%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 0.86% on the day following the earnings release and then changed by -8.10% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of MRNA's latest earnings report for FY2025Q3?
MRNA reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 1.02B against an estimate of 869.89M, resulting in a 16.8% surprise. The EPS was -0.51, surpassing the expected -2.15 by 76.28% . The stock experienced a 3.27% price change on the earnings day and a 12.1% change over the next five days, reflecting market reactions to the results.
How did MRNA's stock price react after the FY2025Q3 earnings release?
Following MRNA's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by 3.27% on the day of the release. Over the subsequent five days, it saw a 12.10% change. Historically, MRNA's stock price tends to shift by an average of +7.79% in the 10 days leading up to earnings and -3.23% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for MRNA for 2025/Q4?
For 2025/Q4, analysts estimate MRNA’s annual revenue to reach 633.09M, while the EPS is projected at -2.76. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.67% and EPS estimates Revise Downward by -14.94% over the past three months, indicating analyst expectation in the company’s performance.
How does MRNA's stock price correlate with earnings forecast revisions?
The correlation between MRNA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -0.67%, while EPS estimates moved Revise Downward by -14.94% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from MRNA's next earnings report?
Based on historical trends, MRNA's stock price typically moves by +7.79% in the 10 days before its earnings and -3.23% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -2.76 and revenue of 633.09M.
What is the sentiment in Moderna Inc (MRNA) Q3 2025 Earnings Call Summary?
The earnings call summary and Q&A reveal concerns about declining vaccination rates, reduced revenue projections, and unclear guidance on future large deals. Despite cost reduction plans and strategic partnerships, the market may react negatively to the reduced revenue guidance and lack of detailed future growth projections. The negative sentiment is reinforced by declining COVID vaccine demand and the cautious outlook on new product launches. These factors suggest a likely negative stock price movement in the short term.